Kresmion signals archive
178 cross-asset signals fired across commodity, crypto, equity, macro.
crypto (16)
USDC/USDT has $188.2M volume but only $884K liquidity - thin market, slippage risk
BTC ETF inflow of $272M - institutional buying
USDUC/SOL crashed -52.0% in 24h on pumpswap DEX
ETH ETF inflow of $116M - institutional buying
USDC/USDT has $199.3M volume but only $884K liquidity - thin market, slippage risk
BTC ETF inflow of $272M - institutional buying
USDUC/SOL crashed -22.1% in 24h on pumpswap DEX
ETH ETF inflow of $116M - institutional buying
USDC/USDT has $169.6M volume but only $884K liquidity - thin market, slippage risk
BTC ETF inflow of $251M - institutional buying
USDC/USDT has $182.2M volume but only $884K liquidity - thin market, slippage risk
BTC ETF inflow of $251M - institutional buying
ETH DEX volume/liquidity ratio elevated (0.57x) - strong on-chain trading activity
SOL DEX volume/liquidity ratio elevated (0.68x) - strong on-chain trading activity
ETH DEX volume/liquidity ratio elevated (0.54x) - strong on-chain trading activity
SOL DEX volume/liquidity ratio elevated (0.78x) - strong on-chain trading activity
equity (152)
FDA approves CLEOCIN PEDIATRIC (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves PROCARDIA XL (Pfizer) - new revenue stream
FDA approves PROCARDIA XL (Pfizer) - new revenue stream
FDA approves PROCARDIA XL (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves AZULFIDINE EN-TABS (Pfizer) - new revenue stream
FDA approves AZULFIDINE EN-TABS (Pfizer) - new revenue stream
FDA approves AZULFIDINE EN-TABS (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves CLEOCIN HYDROCHLORIDE (Pfizer) - new revenue stream
FDA approves CLEOCIN HYDROCHLORIDE (Pfizer) - new revenue stream
FDA approves CLEOCIN HYDROCHLORIDE (Pfizer) - new revenue stream
FDA approves drug (Pfizer) - new revenue stream
FDA approves CLINDAMYCIN PHOSPHATE (Pfizer) - new revenue stream
FDA approves CLINDAMYCIN PHOSPHATE (Pfizer) - new revenue stream
FDA approves CLINDAMYCIN PHOSPHATE (Pfizer) - new revenue stream
FDA approves CLEOCIN PEDIATRIC (Pfizer) - new revenue stream
FDA approves CLEOCIN PEDIATRIC (Pfizer) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Merck) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves drug (Lilly) - new revenue stream
FDA approves FML FORTE (AbbVie) - new revenue stream
FDA approves VUITY (AbbVie) - new revenue stream
FDA approves VUITY (AbbVie) - new revenue stream
FDA approves ZEMPLAR (AbbVie) - new revenue stream
FDA approves ZEMPLAR (AbbVie) - new revenue stream
FDA approves ZEMPLAR (AbbVie) - new revenue stream
FDA approves UBRELVY (AbbVie) - new revenue stream
FDA approves UBRELVY (AbbVie) - new revenue stream
FDA approves UBRELVY (AbbVie) - new revenue stream
FDA approves MAVYRET (AbbVie) - new revenue stream
FDA approves MAVYRET (AbbVie) - new revenue stream
FDA approves MAVYRET (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves OXYTROL FOR WOMEN (AbbVie) - new revenue stream
FDA approves OXYTROL FOR WOMEN (AbbVie) - new revenue stream
FDA approves OXYTROL FOR WOMEN (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves ESTRADIOL (AbbVie) - new revenue stream
FDA approves ESTRADIOL (AbbVie) - new revenue stream
FDA approves ESTRADIOL (AbbVie) - new revenue stream
FDA approves VUITY (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves RINVOQ (AbbVie) - new revenue stream
FDA approves RINVOQ (AbbVie) - new revenue stream
FDA approves RINVOQ (AbbVie) - new revenue stream
FDA approves CELEXA (AbbVie) - new revenue stream
FDA approves CELEXA (AbbVie) - new revenue stream
FDA approves CELEXA (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves drug (AbbVie) - new revenue stream
FDA approves DEPAKOTE ER (AbbVie) - new revenue stream
FDA approves DEPAKOTE ER (AbbVie) - new revenue stream
FDA approves DEPAKOTE ER (AbbVie) - new revenue stream
FDA approves FML FORTE (AbbVie) - new revenue stream
FDA approves FML FORTE (AbbVie) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
FDA approves drug (Abbott) - new revenue stream
Equifax search volume spiked +69 pts - unusual interest
American Water Works search volume spiked +100 pts - unusual interest
General Motors search volume spiked +56 pts - unusual interest
GE Aerospace search volume spiked +53 pts - unusual interest
Evergy search volume spiked +49 pts - unusual interest
Alliant Energy search volume spiked +62 pts - unusual interest
American Water Works search volume spiked +100 pts - unusual interest
Equifax search volume spiked +69 pts - unusual interest
GE Aerospace search volume spiked +53 pts - unusual interest
Evergy search volume spiked +49 pts - unusual interest
Alliant Energy search volume spiked +62 pts - unusual interest
American Water Works search volume spiked +100 pts - unusual interest
AAPL RSI 71.1 - overbought (crossed above 70)
Equifax search volume spiked +69 pts - unusual interest
GE Aerospace search volume spiked +53 pts - unusual interest
General Motors search volume spiked +44 pts - unusual interest
Beat consensus by 15.7% - EPS $4.1 vs $3.544 estimate
Q1-2026: Beat consensus by 7.3% - EPS $1.48 vs $1.3788 estimate
Q2-2026: Beat consensus by 26.4% - EPS $2.69 vs $2.1278 estimate
Q1-2026: Beat consensus by 16.2% - EPS $1.42 vs $1.2221 estimate
Q1-2026: Beat consensus by 21.9% - EPS $1.38 vs $1.1325 estimate
Q1-2026: Beat consensus by 174.8% - EPS $2.95 vs $1.0734 estimate
Evergy search volume spiked +49 pts - unusual interest
Alliant Energy search volume spiked +62 pts - unusual interest
Amcor search volume spiked +69 pts - unusual interest
Adobe Inc. search volume spiked +75 pts - unusual interest
AAPL RSI 71.1 - overbought (crossed above 70)
Equifax search volume spiked +69 pts - unusual interest
GE Aerospace search volume spiked +53 pts - unusual interest
commodity (6)
Oil -6.16% - significant selloff
Oil +2.78% - significant rally
Oil -3.16% - significant selloff
Gold +1.56% - significant rally
Oil -2.04% - significant selloff
Gold +1.29% - significant rally
macro (4)
baltic_dry shipping +5.6% - potential inflation signal
baltic_dry shipping +5.6% - potential inflation signal
baltic_dry shipping +5.6% - potential inflation signal
Financial conditions loosening - NFCI at -0.51, liquidity supportive